Multi-drug resistance (MDR) is a significant challenge in biopharmaceutics, where certain diseases exhibit resistance to multiple medications. This phenomenon often arises in the treatment of cancers and infectious diseases, limiting the effectiveness of therapeutic interventions.
In biopharmaceutics research, combating MDR involves exploring innovative drug delivery systems and formulations that can overcome resistance mechanisms. Nanotechnology, for instance, offers promising solutions by enabling targeted drug delivery, minimizing side effects, and enhancing drug efficacy against resistant strains.
Understanding the molecular basis of MDR is crucial for designing biopharmaceuticals that can bypass or inhibit resistance mechanisms. This knowledge paves the way for the development of next-generation drugs capable of overcoming the challenges posed by multi-drug resistance, thereby improving treatment outcomes and patient care.
Vladlen Slepak
University of Miami, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Anil Pareek
Anand Pharmacy College, India
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Bhasker Sambar
Alvogen Inc, United StatesSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel